baber/WOPTO huggingface dataset:
Patent NZ-562770-A (NZ)
Title: Anti-inflammatory formulation comprising apocynin and paeonol
Inventor: LARKINS NICHOLAS JOHN
IPC: A61K31/216
Filed: 2006-04-07
Abstract: Disclosed herein is a composition comprising apocynin (4-hydroxy-3-methoxyacetophenone) and paeonol (2-hydroxy-4-methoxy-acetophenone), provided that if the composition includes apocynin only in the form of Picrorrhiza kurroa and paeonol which is only in the natural form, the paeonol in the natural form is not in the form of Glycyrrhiza glabra. Such compositions are useful in the treatment of inflammatory diseases.
Patent NZ-563835-A (NZ)
Title: Lift with two lift cages disposed one above the other in a shaft
Inventor: KOCHER HANS SONNMATT
Filed: 2007-11-28
Abstract: A lift with at least two cages 7a, 7b disposed one above the other and vertically movable independently of each other within a single shaft and with each cage having an own drive A1, A2 including at least one motor M1, M2 and at least one drive pulley 1a, 1b, an own counterweight 12a, 12b, and at least one cable Z1, Z2, has the drives fixed respectively to opposite shaft walls so as to be able to be passed by the cages moving in the shaft. Moreover the drive motors M1, M2 are arranged vertically above the associated drive pulleys 1a, 1b.
Patent NZ-565593-A (NZ)
Title: Prediction of transform coefficients for image compression
Inventor: SRINIVASAN SRIDHAR
IPC: H04N19/593
Filed: 2006-08-03
Abstract: A method of encoding digital media data using a predictive coding of transform coefficients is disclosed. A transform is applied to blocks of the digital media data to produce a set of transform coefficients for the respective blocks. The set of transform coefficients of a respective block comprises a DC coefficient for the respective block. Whether one of at least two directionalities of the digital media data in a locality of a current block is dominant is determined. A direction is considered dominant when its directional difference is more than a weighting factor of times that of the other direction. When one of the at least two directionalities is determined to be dominant in the digital media locality of the current block, selecting a predictor of the DC coefficient of the current block according to the determined dominant directionality the DC coefficient of the current block relative to its predictor is encoded. A digital media encoder comprises a data storage buffer for storing the digital media data to be encoded and a processor programmed to encode digital media data using the above described method. A digital media decoder comprises a data storage buffer for storing the digital media data to be encoded and a processor programmed to decode digital media data using a predictive coding of transform coefficients.
Patent NZ-568103-A (NZ)
Title: Catheter for uniform delivery of medication
Inventor: DENIEGA JOSE CASTILLO
IPC: A61F2/958
Filed: 2004-05-11
Abstract: A catheter (250) that delivers fluid medication uniformly across an infusion section of the catheter is disclosed. The catheter has an elongate tubular body (254) of uniform cross-section that defines a lumen (268). The lumen is closed at a distal end (262), while a plurality of openings (266) extend through a side wall of the body near the distal end to define an infusion section. A single-layer tubular sheath (252) of non-expandable diameter is positioned over the infusion section and is permanently attached to the catheter body at either end (264, 265) of the infusion section. The sheath is constructed of a porous material of pore size less than 0.5 microns, where the porous material is a different material than that of the catheter body. Fluid within the lumen exits through one of the openings into an annular interstitial space (270) between the catheter body and the sheath, and then passes only through the porous sheath the exit the catheter.
Patent NZ-568439-A (NZ)
Title: Headspace modification method for removal of vacuum pressure
Inventor: MELROSE DAVID MURRAY
IPC: B65B31/00
Filed: 2008-05-19
Abstract: A container with a seal or cap 80 comprises an aperture or hole that allows the introduction of pressurised fluid 40 into the container and is sealable under pressure providing an increased internal pressure within the container. The process prevents vacuum from forming when hot fill containers cool, and prevents the distortion of the containers.
Patent NZ-571042-A (NZ)
Title: Cream composition for food comprising milk fat, sucrose and water
Inventor: GOTO TAKAKI
IPC: A23L29/20
Filed: 2007-03-29
Abstract: Disclosed is a cream composition, characterized by comprising milk fat, a sugar, and water, wherein the sugar is sucrose, the content of the milk fat is more than 5 mass % and 30 mass % or less, the content of the sugar is 40 to 65 mass %, and the median diameter of the particles in the composition is 0.2 to 4.0 micrometers, and the viscosity of the composition at 20°C is 100 to 2,500 mPa.s.
Patent NZ-574251-A (NZ)
Title: Operating method for a wind park
Inventor: WOBBEN ALOYS
IPC: F03D7/00
Filed: 2004-04-19
Abstract: A wind power installation is disclosed where electrical power which is stored in an electrical energy storage means associated with the wind power installation is consumed to supply the control system of the wind power installation for starting up the wind power installation after stoppage. (62) Divided Out of 543270
Patent NZ-574597-A (NZ)
Title: Stent coated with a biodegradable polymer and rapamycin
Inventor: HOFFMANN ERIKA
IPC: A61F2/82
Filed: 2007-07-03
Abstract: A method for coating a stent with a biodegradable or bioresorbable polymer and rapamycin which comprises coating the stent under the exclusion of light. The polymer is selected from poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PLG), polyvinylpyrrolidone (PVP), polypropylene glycol (PPG), polyethylene glycol (PEG) or polyvinyl alcohol (PVA).
Patent NZ-585250-A (NZ)
Title: Antisense modulation of factor 7 expression
Inventor: FREIER SUSAN M
IPC: C12N15/113
Filed: 2008-11-05
Abstract: Disclosed is a compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides targeted to a Factor 7 nucleic acid, wherein the oligonucleotide has a sequence that is least 90% complementary to SEQ ID NO: 1. Also disclosed is the use of the said compound in the manufacture of a medicament for the treatment of a disease or condition associated with Factor 7 by administering to the animal a therapeutically effective amount of the compound so that expression of Factor 7 is inhibited.
Patent NZ-586208-A (NZ)
Title: A nasal assembly with a vent where at least one end of the vent has a moulding seam positioned out of the main air stream of the vent
Inventor: GUNARATNAM MICHAEL KASSIPILLAI
IPC: A61M16/08
Filed: 2005-04-08
Abstract: A vent assembly comprises at least one vent 619 having a first end configured to face atmosphere, a second end opposite the first end, and a central portion provided between the first and second ends that includes a substantially conical portion having a varying diameter that is larger towards the second end. A substantially cylindrical portion is provided between the first end and the substantially conical portion, and a counter bore is positioned adjacent the first end. At least one of the first and second ends of the vent 619 provides a moulding seam 617a positioned out of the main air stream of the vent 619.
Patent NZ-590930-A (NZ)
Title: Improving the calibration accuracy of a fluidic system by comparing test readings with a calibration curve and then adjusting the signal output
Inventor: HOLMES ELIZABETH A
IPC: A61B5/00
Filed: 2006-03-24
Abstract: A method of improving the accuracy of calibrating a fluidic system, comprises providing a system for detecting an analyte in a bodily fluid from a subject comprising a fluidic device for providing the bodily fluid, the fluidic device having a calibration assembly and a reader assembly for detecting the presence of the analyte, measuring one or more parameters that are fitted to a calibration curve associated with the fluidic device, comparing the one or more parameters with predetermined parameters associate with the fluidic device, and adjusting a signal output by the ratio of the predetermined parameters to the one or more parameters. The fluidic device also has a sample collection unit and an assay assembly where the sample collection unit allows the bodily fluid to react with reactants contained within the assay assembly.
Patent NZ-592743-A (NZ)
Title: A wave-powered vehicle and fin system therefor
Inventor: HINE ROGER G
IPC: B63H1/36
Filed: 2007-01-18
Abstract: A fin system, a wave powered water vehicle, a method of controlling a functional component of the water powered vehicle, and a method of recording data is disclosed. The fin system comprises: (a) a frame having a longitudinal axis; (b) a plurality of fins, where each fin is mounted to the frame and is rotatable about an axis of rotation which is transverse to the longitudinal axis of the frame; and (c) at least one elastically deformable component which is not part of a fin, is linked to at least one fin, and changes shape as the fin rotates about the axis of rotation and thus controls or helps to control the rotation of the fin .
Patent NZ-593208-A (NZ)
Title: Cell-scaffold constructs
Inventor: JAYO MANUEL J
IPC: A61L27/20
Filed: 2009-11-04
Abstract: Disclosed is an implantable construct comprising: a biocompatible matrix shaped to conform to at least a part of a native luminal organ or tissue structure in a subject in need; and a smooth muscle cell (SMC) population deposited on or in a surface of the matrix, wherein the cell population is autologous to the subject and not derived from the native organ or tissue structure.
Patent NZ-597022-A (NZ)
Title: Hemoglobin compositions
Inventor: ABUCHOWSKI ABRAHAM
IPC: A61K38/42
Filed: 2010-06-09
Abstract: NZ 597022 Disclosed is a composition comprising a covalent conjugate between a functional, native haemoglobin molecule and at least one molecule of poly(ethylene glycol), said composition comprising: a water-soluble haemoglobin fraction comprising a group of haemoglobin molecules wherein each member of said group of haemoglobin molecules; is deoxygenated; is covalently conjugated to at least one molecule of said poly(ethylene glycol) through an amine moiety of an amino acid residue; is substantially free of chemical cross-linking agents; includes less than 5% cross-linked haemoglobin; and has a P50 of from about 9 mm Hg to about 12 mm Hg; a water-soluble stabiliser fraction rendering said group of haemoglobin molecules oxidation resistant, said fraction comprising, a stabilising agent comprising a structural element more reactive with oxygen than said group of haemoglobin molecules; and a diluent fraction comprising, a pharmaceutically acceptable diluent in which said hemoglobin fraction is soluble, said composition being essentially free of viral activity, and stably comprising less than about 10% methemoglobin.
Patent NZ-599351-A (NZ)
Title: Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis
Inventor: DEKELVER RUSSELL
IPC: C12N5/04
Filed: 2010-10-22
Abstract: 599351 Disclosed is a synthetic or recombinant zinc finger protein that modulates expression of a β-ketoacyl-ACP synthetase (KAS) gene, wherein the zinc finger protein comprises five or six zinc finger recognition regions designated and ordered F1 to F5 for a five finger protein or F1 to F6 for a six finger protein, as shown in a single row of Table 1, wherein the zinc finger protein binds to a target site in the KAS gene. ZFP F1 F2 F3 F4 F5 F6 13685 RSDNLSV QKINLQV RSDTLSE TRSSRIN RSDALAR N/A 13714 RSDHLSA TSSSRIN RSDNLAR DRSHLAR RSDNLSE RNAHRTT 13722 QSGNLAR RSDHLSE QKANRTK RSDDLTR TSANLSR N/A 13743 RSDDLSK RSANLTR RSDDLTR RSDHLSE DKSNRKK N/A
Patent NZ-600132-A (NZ)
Title: Folding exercise rowing machine
Inventor: COFFEY CALVIN T
IPC: A63B69/06
Filed: 2010-11-01
Abstract: 600132 A fold-down exercise rowing machine, which is collapsible to occupy less space, is disclosed. The fold-down rowing machine comprises an elongated frame (12) with a pair of seat rail members (14, 16) extending at least a portion of the distance between proximal and distal ends of the elongated frame. A foot plate (30) is mounted on the frame at the distal end thereof. A rotary flywheel (80) is mounted at the proximal end of the frame below the seat rail members to rotate on a vertical axis, with a vertical spacing (see D, figure 8) being defined between the flywheel and the seat rail members. A seat (34) is movably supported on the seat rail members and is adapted to glide along the seat rail members. At least one arm (42) is pivotally connected onto a vertical fixed pivot member (46) on a respective left or right side of the frame. An oar pivot member (49) is rotatably supported in the fixed pivot member, with an oar handle shaft (50) affixed onto an upper end of the oar pivot member. A pulling member (48) is mounted onto the lower end of the oar pivot members. A power cable arrangement (62) has a portion thereof winding around a drive sprocket (see 84, figure 9) of the flywheel such that when a user is seated on the seat and strokes the oar handle shaft the flywheel is roated. A resilient return mechanism (see 76, figure 9) applies a tension onto the power cable arrangement against the stroke action of the oar handle shaft. The at least one arm is adapted to pivot between an extended position in which the arm protrudes horizontally out from the frame and a withdrawn position in which the arm is deflected towards the frame; a releasable latch mechanism holds said arm in said extended position during exercise use of the machine, and is adapted to release to permit the arm to swing to its withdrawn position. The cable pulling member has a thickness less than the vertical spacing (D) to permit said cable pulling member to fit between the flywheel and the seat rail members when the arm is in the withdrawn position to advantageously provide a more compact stowage arrangement.
Patent NZ-600231-A (NZ)
Title: Pharmaceutical compositions comprising sigma receptor ligands
Inventor: SOLER RANZANI LUIS
IPC: A61K9/16
Filed: 2010-11-25
Abstract: 600231 Disclosed herein is a pharmaceutical composition that comprises a compound of formula (I) as active pharmaceutical ingredient: or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof; and at least a pharmaceutically acceptable excipient, wherein the active pharmaceutical ingredient is present in an amount of at least 80% of the total dry weight of the composition.
Patent NZ-600769-A (NZ)
Title: Diaper including elastic and inelastic zones at waist
Inventor: HASHINO YUKI
IPC: A61F13/15
Filed: 2010-12-16
Abstract: A diaper (10) includes front and rear waist members (20, 30), a crotch member (40) by the intermediary of which these front and rear waist members are connected. The front and rear waist members extend from waist ends (22, 32) toward the side of a crotch region (13) and respectively include first regions (71) overlapping front and rear end flaps (46, 47) of the absorbent structure (41) and second regions (72) adjacent the respective first regions. In the front and rear waist members the first regions and the second regions are provided with first waist elastic members (81) and second waist elastic members (82) so as to be sandwiched between the respective top sheets (24, 25) and back sheets (34, 35). The respective second regions are formed with inelastic zones (72a) overlapping the core (42) and elastic regions (72b) lying on both sides of the inelastic regions in the transverse direction. The tightening force of the respective first regions are set to be lower than the tightening force of the respective second regions.
Patent NZ-601377-A (NZ)
Title: Ph adjusted soy protein isolate and uses
Inventor: CATIPON EDWIN
IPC: A23J3/16
Filed: 2010-12-22
Abstract: Disclosed is a soy protein product having a protein content of at least 60 wt% (N x 6.25) d.b. with a pH of 6 and which has a non-beany flavour, the soy protein product being highly soluble in water at pH 2 to 3 and poorly soluble in water over a pH range from 4 to 6. Also disclosed is a method of producing said soy protein product which includes: - providing an aqueous solution of a soy protein product having a protein content of at least 60 wt% (N x 6.25) d.b. which is completely soluble in aqueous media at a pH of less than 4.4 and heat stable at that pH range; - adjusting the pH of the solution to pH 6 to precipitate soy protein therefrom; and - drying the resulting product; or - recovering and drying the precipitated material.
Patent NZ-602084-A (NZ)
Title: Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
Inventor: MOYO VICTOR
IPC: C07K16/32
Filed: 2011-03-11
Abstract: Disclosed is the use of an ErbB3 inhibitor for preparation of a medicament for treating triple negative breast cancer, wherein the inhibitor is an anti-ErbB3 antibody. The preferred anti-ErbB3 antibody is designated MM-121 and is as defined in the complete specification.
Patent NZ-602725-A (NZ)
Title: Condenser for axial flow exhaust type steam turbine and geothermal power plant having the same
Inventor: KAMIHASHI YUKO
IPC: F01D25/32
Filed: 2012-09-28
Abstract: 602725 Disclosed is a condenser for an axial flow exhaust type steam turbine and a geothermal power plant capable of ensuring nozzle pressure, reducing construction cost, and preventing water induction in the condenser for the axial flow exhaust type steam turbine. The condenser comprises a condenser unit which condenses steam exhausted from the steam turbine by directly contacting cooling water from a spray nozzle with the steam and a cooling tower which receives water condensed by the condenser unit, cools the condensed water with air-cooling to generate the cooling water, and accumulates the cooling water. A water circulating pipe which supplies water condensed by the condenser unit to the cooling tower and a water return circulating pipe which supplies the cooling water received and accumulated by the cooling tower to the condenser unit. A pump is connected to the water return circulating pipe performs so that the required pressure of the spray nozzle is equal to a value which is obtained by subtracting a static head difference between the upper most height for installing a spray nozzle of the condenser unit and a water surface level of the cooling tower from the pressure difference between the surface pressure in the cooling tower and the inner pressure of the condenser unit. A valve is connected to, and is capable of shutting-off the water return circulating pipe.
Patent NZ-602728-A (NZ)
Title: Package for containers
Inventor: FORD COLIN
IPC: B65D71/12
Filed: 2011-05-19
Abstract: A carrier (1) that is at least partially holding a plurality of containers (C) that have flaps (F) is disclosed. The carrier includes a plurality of panels comprising a bottom panel (11), a first side panel (13) foldably connected to the bottom panel, a second side panel (17) foldably connected to the bottom panel, a first top panel (21) foldably connected to the first side panel, and a second top panel (25) foldably connected to the second side panel. There is at least one container-receiving feature (75) in the bottom panel. The container-receiving feature receives at least one container of the plurality of containers. At least one retention flap (29) is foldably connected to the first top panel or the second top panel at a series of spaced-apart lateral fold lines 31. The at least one retention flap engages at least a portion of a flange (F) of at least one container. In the embodiment illustrated each first container-receiving feature (75) defines a first brace flap (79) foldably attached to the first side panel (13) at the lateral fold line (15) and a second brace flap (81- Fig 8) foldably connected to the bottom panel (11) at a respective lateral fold line. A blank and method of forming is also disclosed.
Patent NZ-605627-A (NZ)
Title: Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
Inventor: CHARRIER JEAN-DAMIEN
IPC: C07D519/00
Filed: 2011-06-23
Abstract: Disclosed are 2-(4-isopropylsulfonylphenyl)-pyrrolo[2,3-b]pyrazine derivatives and analogues as represented by the general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl substituted with one or two occurrences of J, where J is an aliphatic group which incorporates an S(O)2 group; A is an optionally substituted aryl, heteroaryl ring or a substituted alkynyl moiety; and wherein the remaining substituents are as defined herein. Representative compounds include 2-(4-isopropylsulfonylphenyl)-7-(3-pyridyl)-5H-pyrrolo[2,3-b]pyrazine, 2-(4-isopropylsulfonylphenyl)-7-(2-phenylethynyl)-5H-pyrrolo[2,3-b]pyrazine, 5-[2-(4-isopropylsulfonylphenyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-3-phenyl-isoxazole, 2-(4-isopropylsulfonylphenyl)-7-(2-cyano-phenyl)-5H-pyrrolo[2,3-b]pyrazine, 2-(4-isopropylsulfonylphenyl)-7-(5-amino-pyrazin-2-yl)-5H-pyrrolo[2,3-b]pyrazine, 2-(2-(4-isopropylsulfonylphenyl)-pyrrolo[2,3-b]pyrazin-7-yl)phenol and 2-(4-isopropylsulfonylphenyl)-7-(4-methyl-thiophen-3-yl)-5H-pyrrolo[2,3-b]pyrazine. Also disclosed is a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable carrier, for treating cancer (such as lung cancer, head and neck cancer, pancreatic cancer, gastric cancer, and brain cancer), for promoting cell death in cancer cells, for preventing cell repair from DNA damage, for sensitizing cells to DNA damaging agents.
Patent NZ-608285-A (NZ)
Title: Manufacturing process for pyrimidine derivatives
Inventor: CALIENNI JOHN VINCENT
IPC: C07D401/04
Filed: 2011-09-29
Abstract: This disclosure relates to processes for manufacturing a compound of formula (5) or a stereoisomer, tautomer or a salt thereof. In the compound, W can be a substituted carbon or a nitrogen and R1 to R4 can have various substitutions as described in the specification. Compounds of formula (5), with a morpholine and pyrimidine moieties, are PI3K inhibitors.
Patent NZ-612961-A (NZ)
Title: Pyrimidine gyrase and topoisomerase iv inhibitors
Inventor: PEROLA EMANUELE
IPC: C07F9/6558
Filed: 2012-01-13
Abstract: NZ 612961 The disclosure relates to solid forms of compound of formula (I) and pharmaceutically acceptable salts thereof, wherein the variables X and R are as defined herein, particularly the methanesulfonic acid salt, which inhibit bacterial enzymes gyrase and/or topoisomerase IV. The compounds of formula (I) either possess a broad range of anti bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity. Also disclosed are pharmaceutical compositions comprising said compound of formula (I) or its salts and their use for treating nosocomial or a non-nosocomial bacterial infections which are characterized by the presence of one or more of Streptococcus pneumoniae, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus aureus, Clostridium difJicile, Moraxella catarrhalis, Neisseria gonorrhoeae, Neisseria meningitidis, ycobacterium avium complex, Mycobacterium abscessus, Mycobacterium kansasii, Mycobacterium ulcerans, Chlamydophila pneumoniae, Chlamydia trachomatis, Haemophilus injluenzae, Streptococcus pyogenes or β-haemolytic streptococci.
Patent NZ-617447-A (NZ)
Title: Anti-nerve growth factor antibodies and methods of preparing and using the same
Inventor: GEARING DAVID
IPC: C07K16/46
Filed: 2012-05-08
Abstract: Disclosed is an antibody or an antigen binding fragment thereof which is capable of specifically binding to feline neuronal growth factor (NGF) and inhibiting the ability of feline NGF to bind to the p75 or TrkA feline NGF receptor, wherein the antibody or antigen binding fragment comprises the heavy and light chains of the sequences as disclosed in the specification; wherein the antibody or antigen binding fragment thereof does not contain any amino acid in any position within the framework regions which would be foreign at the position in one or more feline antibodies. Also disclosed is a method for preparing such antibodies.